Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Zacks Investment Research

15 Jun 2026, 15:45 UTC · 2h ago

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

What the story claims

4 claims · each scored for market impact

What matters in this story

1
The FDA has accepted the New Drug Application (NDA) for zilurgisertib to treat fibrodysplasia ossificans progressiva (FOP) and granted it Priority Review status. — FDA acceptance and Priority Review significantly accelerate the timeline to potential commercialization, creating a high-probability catalyst for the affected companies.
+0.80
2
Zilurgisertib met its primary endpoint by significantly reducing new heterotopic ossification (HO) lesion formation in a pivotal phase II study. — Positive clinical data validates the drug's efficacy, reducing the risk of failure before the FDA's final decision.
+0.60
3
The FDA is expected to deliver a decision regarding the NDA for zilurgisertib by September 26, 2026. — Provides a concrete date for a binary market event, though the distant timeframe limits immediate volatility.
+0.30
4

6 related stories

Proactive Investors
5h ago
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome
- biotech
- clinical trials
- healthcare
Read

MIRM, INCY Report Positiv… — INCY +1.00 | NewsImpactScreener

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

What matters in this story

Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

What matters in this story

Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Nordicus Partners Corporation Corporate Update

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

What matters in this story

Next reads from the same story arc

Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome

MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review

What matters in this story

Next reads from the same story arc

Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome

How each ticker is affected

Connected tickers

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging

Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress

Nordicus Partners Corporation Corporate Update

WSTPR Catalyst Watch: NeOnc Strengthens Capital Position Ahead of Potentially Transformational Neuro-Oncology Updates

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers